ITUS Corporation Announces Proposed Public Offering of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
76
ITUS Corporation Announces Proposed Public Offering of Common Stock

LOS ANGELES, CA --(Marketwired - May 10, 2017) - ITUS Corporation ( ITUS ) ( NASDAQ : ITUS ), a company using the power of the immune system to diagnose cancer, today announced a proposed registered public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Dawson James Securities, Inc., is acting as exclusive placement agent for the offering.

ITUS intends to use the net proceeds from the offering, if completed, for working capital and general corporate purposes, including the potential payment of corporate debt.

The shares are being offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-206782), that was previously filed with the Securities and Exchange Commission (SEC) and declared effective on September 18, 2015. The securities may be offered only by means of a prospectus. The prospectus has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov . The preliminary prospectus supplement related to the offering will be available on the SEC's website located at http://www.sec.gov and may also be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, mmaclaren@dawsonjames.com , or toll free at 866.928.0928.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

ITUS Corporation

ITUS funds, develops, acquires, and licenses emerging technologies in areas such as biotechnology. The Company is developing a platform called Cchek™, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Additional information is available at www.ITUScorp.com .

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™

Contact: Dean Krouch (310) 484-5184 dkrouch@ITUScorp.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 249

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Tencent Cloud's Edge Platform Shines in New Gartner Report

Updated Category News Views 61

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 307

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 138

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 203

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 76

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
AI Shopping Surge: WeFetch.ai's Bold Rebrand Move

Updated Category News Views 48

Shifting Gears: GreenCore Solutions Becomes WeFetch.ai Here's a shift you don't see every day. GreenCore Solutions has morphed into WeFetch.ai, aiming to sail the ever-growing AI shopping seas. This isn't just a new nameplate; it's a declaration of intent to dive headfirst into the market dynamics driven by artificial intelligence. It's bold and, frankly, pretty timely....

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 149

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Mako Hiraizumi Shines with Silver at Japan Triathlon

Updated Category News Views 41

A Triathlete with Grit and Ambition Mako Hiraizumi didn't just earn a silver medal at the 32nd Japan Triathlon National Championships; she set an example of perseverance and ambition. Rising a notch from her bronze finish last year, Hiraizumi's runner-up achievement at Tokyo's Odaiba Seaside Park is no small feat. Yet, she's not resting on her laurels. This athlete from...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 482

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Abeona Therapeutics' ZEVASKYN Receives FDA Approval, a New Hope

Updated Category News Views 147

A Revolutionary Breakthrough for Epidermolysis Bullosa In an incredible achievement for the EB community, Abeona Therapeutics has received FDA approval for ZEVASKYN, which is poised to change the landscape for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). This marks a historic moment as the third FDA-approved treatment for RDEB and the first autologous,...

Continue Reading
Zero Candida Reaches Major Milestone with ZC-001 Device Development

Updated Category News Views 127

Zero Candida Marks Milestone with ZC-001 Prototype Production Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) has achieved a remarkable milestone in its quest to revolutionize women's health. The company recently announced the commencement of prototype production for its groundbreaking therapeutic device, ZC-001, designed specifically for the treatment of...

Continue Reading
Bitcoin's Future and Market Dynamics: Insights from a Veteran Trader

Updated Category News Views 86

Cautious Optimism for Bitcoin and Other Cryptocurrencies Pseudonymous veteran trader DonAlt expresses a cautious outlook on leading cryptocurrencies like Bitcoin, Ethereum, and Dogecoin. His insights on market trends reveal an intriguing perspective for investors in these digital assets. Current Market Situation DonAlt has recently shared his thoughts on the performance...

Continue Reading
Alibaba Settles for $433.5 Million in Shareholder Lawsuit

Updated Category News Views 220

Alibaba Reaches Settlement in Lawsuit Alibaba (NYSE: BABA), China’s leading e-commerce powerhouse, has recently taken a significant step in addressing legal challenges by agreeing to pay $433.5 million to settle a class-action lawsuit in the United States. This lawsuit, brought forth by investors, accused Alibaba of engaging in monopolistic practices. The company's...

Continue Reading
Class Action Alert: Telix Pharmaceuticals Lawsuit Overview

Updated Category News Views 174

Understanding the Telix Pharmaceuticals Class Action In a significant development, investors of Telix Pharmaceuticals Limited are currently facing a class action lawsuit. This initiative, spearheaded by Bronstein, Gewirtz & Grossman LLC, invites those affected by substantial losses in their investments to take action. The law firm is renowned for its dedication in...

Continue Reading